FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Zydus

Drug and asset intelligence for Zydus with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Stage: Development stage unavailable

Mechanism of action

Combination Therapy

Recent signals(3)

RegulatoryJuly 23, 2026

Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

Zydus Pharms has received an Abbreviated New Drug Application (ANDA) approval status for Dexmedetomidine Hydrochloride.

StrategyJuly 21, 2026

FDA Grants AP Status for Zydus' Oxcarbazepine ANDA211747

The FDA has granted Abbreviated Approval (AP) status for Zydus' ANDA211747 for oxcarbazepine.

StrategyJuly 9, 2026

Zydus Pharms submits ANDA for Metformin Hydrochloride and Sitagliptin Phosphate

Zydus Pharms USA Inc. has submitted an ANDA for a combination product of Metformin Hydrochloride and Sitagliptin Phosphate.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Therapeutic areas

Anesthesia →

Antiepileptic →

Combination Therapy →

Diabetes →

Neurology →

Sedative →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.